Predictive Factors of Disease-free Survival After Complete Pathological Response to Neoadjuvant Radiotherapy in Rectal Adenocarcinoma

Predictive Factors of Disease-free Survival After Complete Pathological Response to Neoadjuvant Radiotherapy in Rectal Adenocarcinoma

Ver estudio completo en Inglés
Patrocinadores

Patrocinador principal: Moroccan Society of Surgery

Fuente Moroccan Society of Surgery
Resumen breve

Many data suggest that patients with low rectal adenocarcinoma who achieved ypT0N0 status have improved survival and disease-free survival (DFS) compared to all other stages however only few data are available regarding the specific prognosis factors of this subgroup. This retrospective multicentric study aimed to predict the prognosis of patients with complete pathological response after neoadjuvant treatment.

Estado general Completed
Fecha de inicio January 1, 2005
Fecha de Terminación March 31, 2016
Fecha de finalización primaria December 31, 2013
Tipo de estudio Observational
Resultado primario
Medida Periodo de tiempo
Local recurrence rate From date of surgery until the date of first documented local progression assessed up to 100 months
Distant recurrence rate From date of surgery until the date of first documented distant progression assessed up to 100 months
Resultado secundario
Medida Periodo de tiempo
Predictive factors of disease free survival From date of surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Inscripción 84
Condición
  • Rectal Neoplasms
Intervención

Tipo de intervención: Procedure

Nombre de intervención: rectal resection

Descripción: total mesorectal excision

Elegibilidad

Método de muestreo: Non-Probability Sample

Criterios:

Inclusion Criteria

- patients with a histologically proven low rectal adenocarcinoma,

- no previous or synchronous colorectal disease,

- UICC stage I-III patients who underwent neoadjuvant chemoradiotherapy or chemotherapy,

- followed by total mesorectal excision (TME), and

- a complete pathological response defined as ypT0N0

Exclusion Criteria:

- all patients with metastatic tumors or missing data

Género: All

Edad mínima: 18 Years

Edad máxima: N/A

Voluntarios Saludables: No

Ubicación
Instalaciones:
Batna anticancer center | Alger, Algeria
Mohammed V University Medical School, Surgery Department, Military Hospital | Rabat, Please Enter The State Or Province, 10001, Morocco
Mohammed V University Medical School, Surgical Department "A", Ibn Sina Hospital | Rabat, Please Enter The State Or Province, 10001, Morocco
Mohammed V University Medical School, Surgical Department "C", Ibn Sina Hospital, | Rabat, Please Enter The State Or Province, 10001, Morocco
National Institut of Oncology, Surgical oncology department | Rabat, Please Enter The State Or Province, 10001, Morocco
Sidi Mohammed Ben Abdellah University Medical School, Surgery Department, | Fès, Morocco
Mohammed Ist University Medical School, Surgical Oncology, Hospital el Farabi | Oujda, Morocco
Private surgical oncology center | Salé, Morocco
Ubicacion Paises

Algeria

Morocco

Fecha de verificación

July 2018

Fiesta responsable

Tipo: Sponsor

Palabras clave
Tiene acceso ampliado No
Condición Examinar
Datos del paciente Undecided
Información de diseño del estudio

Modelo de observación: Cohort

Perspectiva de tiempo: Retrospective

Source: ClinicalTrials.gov